125 related articles for article (PubMed ID: 15714348)
1. Costs of treatment of colorectal cancer in different settings in Germany.
Hieke K; Kleeberg UR; Stauch M; Grothey A
Eur J Health Econ; 2004 Oct; 5(3):270-3. PubMed ID: 15714348
[TBL] [Abstract][Full Text] [Related]
2. Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds.
Grothey A; Kleeberg UR; Stauch M; Hieke K
Z Gastroenterol; 2005 Feb; 43(2):155-61. PubMed ID: 15700205
[TBL] [Abstract][Full Text] [Related]
3. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands.
Jansman FG; Postma MJ; van Hartskamp D; Willemse PH; Brouwers JR
Clin Ther; 2004 Apr; 26(4):579-89. PubMed ID: 15189755
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Con: Pumpin' FU (or, avoiding that oral fixation).
Hochster HS
Clin Adv Hematol Oncol; 2005 May; 3(5):405-6. PubMed ID: 16167014
[No Abstract] [Full Text] [Related]
6. Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Cassidy J; Schmoll HJ; Van Cutsem E
J Clin Oncol; 2008 May; 26(13):2226-7; author reply 2228. PubMed ID: 18445855
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.
Shiroiwa T; Fukuda T; Shimozuma K; Ohashi Y; Tsutani K
Pharmacoeconomics; 2009; 27(7):597-608. PubMed ID: 19663530
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients.
Chen HH; Chen WT; Lee HC; Lin JK; Fang CY; Chou YH; Lin PC; Lin BW; Huang CC; Yeh CH; Hsu HH; Chen HC; Ting WC; Yang MC; Tan EC
Qual Life Res; 2015 Feb; 24(2):473-84. PubMed ID: 25099199
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer.
Best JH; Garrison LP
Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):103-14. PubMed ID: 20384557
[TBL] [Abstract][Full Text] [Related]
10. The CAP-CR study: direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine.
Lopatriello S; Amoroso D; Donati S; Alabiso O; Forti L; Fornasiero A; Smergo A; Lalli A; Iacono C; Lucenti A; D'Alonzo L; Negrini C
Eur J Cancer; 2008 Nov; 44(17):2615-22. PubMed ID: 18805000
[TBL] [Abstract][Full Text] [Related]
11. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
Twelves CJ
Clin Colorectal Cancer; 2006 Nov; 6(4):278-87. PubMed ID: 17241512
[TBL] [Abstract][Full Text] [Related]
12. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence.
Comella P; Casaretti R; Sandomenico C; Avallone A; Franco L
Drugs; 2008; 68(7):949-61. PubMed ID: 18457461
[TBL] [Abstract][Full Text] [Related]
14. Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients.
De Portu S; Mantovani LG; Ravaioli A; Tamburini E; Bollina R; Cozzi C; Grimaldi AM; Testa TE; Bianchessi C; Carteni G
J Chemother; 2010 Apr; 22(2):125-8. PubMed ID: 20435573
[TBL] [Abstract][Full Text] [Related]
15. Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting.
Douillard JY; Tilleul P; Ychou M; Dufour P; Perrocheau G; Seitz JF; Maes P; Lafuma A; Husseini F
Oncology; 2007; 72(3-4):248-54. PubMed ID: 18185019
[TBL] [Abstract][Full Text] [Related]
16. [Economic evaluation of capecitabine use as first line treatment in patients with advanced gastric carcinoma in Portugal].
Macedo A; Pereira C; Gonçalves J; Sousa C
Acta Med Port; 2009; 22(6):827-32. PubMed ID: 20350467
[TBL] [Abstract][Full Text] [Related]
17. Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
Tran G; Hack SP; Kerr A; Stokes L; Gibbs P; Price T; Todd C
Asia Pac J Clin Oncol; 2013 Sep; 9(3):239-48. PubMed ID: 23279720
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer.
Chu E; Cartwright TH
J Clin Oncol; 2008 May; 26(13):2224-6; author reply 2228. PubMed ID: 18445854
[No Abstract] [Full Text] [Related]
19. Adjuvant chemotherapy for colon cancer--analysis of treatment costs from the perspective of statutory sickness funds.
Görner M; Riemer-Hommel P
Z Gastroenterol; 2008 Jul; 46(7):681-8. PubMed ID: 18618379
[TBL] [Abstract][Full Text] [Related]
20. Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.
Perrocheau G; Bennouna J; Ducreux M; Hebbar M; Ychou M; Lledo G; Conroy T; Dominguez S; Faroux R; Florentin V; Douillard JY
Oncology; 2010; 79(3-4):174-80. PubMed ID: 21358204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
